Therefore, we estimated the response of adjacent DCIS to NST-containing HER2-blockade in HER2-positive breast cancer patients and assessed the association of clinicopathological and radiological factors with response. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.